c1ac46ad-639c-4ac2-b8d2-3cd97201c0e820250527080643544wseas:wseasmdt@crossref.orgMDT DepositMOLECULAR SCIENCES AND APPLICATIONS2732-99922944-913810.37394/232023https://wseas.com/journals/msa/index.php42320254232025510.37394/232023.2025.5https://wseas.com/journals/msa/2025.phpOmar M. E.Abdel-SalamDepartment of Toxicology and Narcotics Medical Research and Clinical Studies Institute, National Research Centre Tahrir Street, Dokki, Cairo EGYPTMarawan AbdEl BasetDepartment of Pharmacology Medical Research and Clinical Studies Institute, National Research Centre Tahrir Street, Dokki, Cairo EGYPTFatma A.MorsyDepartment of Pathology Medical Research and Clinical Studies Institute, National Research Centre Tahrir Street, Dokki, Cairo EGYPTAmany A.SleemDepartment of Pharmacology Medical Research and Clinical Studies Institute, National Research Centre Tahrir Street, Dokki, Cairo EGYPTCannabis, recognized as the most prevalent illegal drug globally, has been linked to various acute cardiovascular incidents, including arrhythmias such as premature ventricular contractions, ventricular tachycardia, sinus arrest, and myocardial infarction. We investigated the effect of cannabis extract on electrocardiographic parameters and cardiac histology in anaesthetized normal rats and in epinephrine-induced arrhythmia and myocardial damage anaesthetized rat model. Male Sprague-Dawley rats were treated with cannabis extract (10 or 20 mg/kg  9 -THC) given intraperitoneally (i.p.) for one week prior to intravenous (i.v.) saline or epinephrine. The control group received saline. Results indicated that (i) the repeated administration of cannabis at 10 or 20 mg/kg in normal rats caused dose-dependent and significant bradycardia (heart rate decreased by 15.7% and 24.0%, respectively), and shortened QRS duration by 8% and 16%, respectively. The QTc interval was prolonged by 28.6% and 52.9% and R wave amplitude increased by 30.5% and 38.7% following the administration of 10 and 20 mg/kg cannabis, respectively. The ST segment was depressed after 10 and 20 mg/kg cannabis; (v) In contrast, rats pretreated with cannabis prior to i.v. epinephrine, exhibited increased the heart rate by 46.3% and 91.4%, and decreased P-R interval by 18.6% and 30% compared with the epinephrine control values. Cannabis at 10 and 20 mg significantly decreased the QRS duration by 21.6% and 18.7% while significantly increased the QTc interval by 17.9% and 22.6%, respectively. In addition, cannabis at 10 mg/kg induced a significant inversion of the ST-segment, while the higher dose resulted in significantly raised ST segment, compared with the corresponding epinephrine control; (vi) administration of cannabis was associated with a significant and dose-related suppression of the epinephrine arrhythmia; (vii) cannabis caused disorganization of cardiac muscle fibers, nuclear pyknosis, interstitial inflammatory cell invasion, vacuolar degeneration and hyalinization of muscle fibers. Epinephrine-treated rats showed coagulative necrosis, shrunken nuclei and focal degeneration of cardiac muscle fibers. Notably, rats receiving 20 mg/kg of cannabis prior to epinephrine treatment exhibited extensive degeneration and coagulative necrosis of cardiac muscle fibers. Collectively, these results show that the repeated administration of cannabis in high doses caused bradycardia, QTc prolongation, and ST changes suggestive of myocardial ischaemia. Cannabis caused structural myocardial damage and aggravated that caused by epinephrine. Repeated cannabis administration did not increase epinephrine arrhythmia.5272025527202528404https://wseas.com/journals/msa/2025/a08msa-004(2025).pdf10.37394/232023.2025.5.4https://wseas.com/journals/msa/2025/a08msa-004(2025).pdf10.18356/9789210019545c005UNODC, World Drug Report (United Nations publication, 2024), [Online]. Vienna, Austria. https://www.unodc.org/unodc/en/data-andanalysis/world-drug-report-2024. (Accessed Date: Feb 20, 2025). Huestis MA. Cannabis (marijuana)—effects on human behavior and performance. Forensic Science Review, Vol. 14, 2012, pp.15. 10.1016/s0040-4039(00)90646-4Mechoulam R, Gaoni Y. The absolute configuration of delta-1-tetrahydrocannabinol, the major active constituent of hashish. Tetrahedron Letters, Vol, 12, 1967, pp. 1109- 1111. 10.1177/2398212818783908Hourani W, Alexander SPH. Cannabinoid ligands, receptors and enzymes: Pharmacological tools and therapeutic potential. Brain and Neuroscience Advances, Vol.2:2398212818783908, 2018. doi: 10.1177/2398212818783908. 10.1503/cmaj.202392Ladha KS, Mistry N, Wijeysundera DN, Clarke H, Verma S, Hare GMT, Mazer CD. Recent cannabis use and myocardial infarction in young adults: a cross-sectional study. Canadian Medical Association Journal, Vol. 193, No. 35, 2021, pp. E1377-E1384. doi: 10.1503/cmaj.202392. 10.3390/cells11071142Weresa J, Pędzińska-Betiuk A, Mińczuk K, Malinowska B, Schlicker E. Why Do marijuana and synthetic cannabimimetics induce acute myocardial infarction in healthy young people? Cells, Vol. 11, No. 7, 2022, pp.1142. doi: 10.3390/cells11071142. 10.1186/s12872-023-03566-4Licciardi M, Utzeri E, Marchetti MF, Nissardi V, Cecchetto G, Montisci M, Montisci R. Syncope and Cannabis: hypervagotonia from chronic abuse? A case report and literature review. BMC Cardiovascular Disorders, Vol. 23, No. 1, 2023, pp. 518. doi: 10.1186/s12872- 023-03566-4. 10.7759/cureus.16202Malviya A, Khan SA, Gupta A, Mishra A. Chronic marijuana consumption leading to high-grade atrioventricular block in a young male. Cureus, Vol. 13, No. 7, 2021, pp. e16202. doi: 10.7759/cureus.16202. 10.1093/ehjcr/ytaa376Yahud E, Paul G, Rahkovich M, Vasilenko L, Kogan Y, Lev E, Laish-Farkash A. Cannabis induced cardiac arrhythmias: a case series. European Heart Journal - Case Reports, Vol. 4, No. 6, 2020, pp.1-9. doi: 10.1093/ehjcr/ytaa376. 10.1016/j.amjcard.2022.05.004Harding BN, Austin TR, Floyd JS, Smith BM, Szklo M, Heckbert SR. Self-reported marijuana use and cardiac arrhythmias (from the Multiethnic Study of Atherosclerosis). American Journal of Cardiology, Vol. 177, 2022, pp. 48-52. doi:10.1016/j.amjcard.2022.05.004. 10.1161/jaha.123.030178Jeffers AM, Glantz S, Byers AL, Keyhani S. Association of cannabis use with cardiovascular outcomes among US adults. Journal of the American Heart Association, Vol. 13, No. 5, 2024, pp. e030178. doi: 10.1161/JAHA.123.030178. 10.1111/ajad.13215Patel RS, Gonzalez MD, Ajibawo T, Baweja R. Cannabis use disorder and increased risk of arrhythmia-related hospitalization in young adults. The American Journal on Addictions, Vol. 30, 2021, pp.578-584. https://doi.org/10.1111/ajad.13215 10.26828/cannabis.2018.01.004Robinson JA, Somasegar S, Shivapour JK, Snyder CS. ECG findings in pediatric patients under the influence of marijuana. Cannabis. Vol. 1, No. 1, 2018, pp.28-34. doi: 10.26828/cannabis.2018.01.004 Zubrzycki M, Liebold A, Janecka A, Zubrzycka M. A new face of endocannabinoids in pharmacotherapy. Part I: protective role of endocannabinoids in hypertension and myocardial infarction. Journal of Physiology and Pharmacology, Vol. 65, No. 2, 2014, pp.171-81. 10.5772/62822Kaschina E. Cannabinoid CB1/CB2 Receptors in the Heart: Expression, Regulation, and Function. In: Meccariello R, Chianese R (Eds.), Cannabinoids in Health and Disease 2016. https://www.intechopen.com/chapters/50317.d oi: 10.5772/62822 10.1038/sj.bjp.0702337Niederhoffer N, Szabo B. Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation. British Journal of Pharmacology, Vol. 126, No. 2, 1999, pp. 457-66. doi: 10.1038/sj.bjp.0702337. 10.1007/s00210-004-1003-9Pfitzer T, Niederhoffer N, Szabo B. Search for an endogenous cannabinoid-mediated effect in the sympathetic nervous system. NaunynSchmiedeberg's Archives of Pharmacology, Vol. 371, No. 1, 2005, pp. 9-17. doi: 10.1007/s00210-004-1003-9. 10.1016/s0022-3565(24)39125-6Niederhoffer N, Szabo B. Cannabinoids cause central sympathoexcitation and bradycardia in rabbits. The Journal of Pharmacology and Experimental Therapeutics, Vol. 294, No. 2, 2000, pp.707-13. 10.37394/23208.2025.22.2Abdel-Salam OME, Abd El Baset M, Morsy FA, Sleem AA. The acute effects of cannabis on cardiac arrhythmia and myocardial injury induced by epinephrine in the rat. WSEAS Transactions on Biology and Biomedicine, Vol. 22, 2025, pp. 14-25. 10.1016/b978-0-12-044620-9.50010-5Turner JC, Mahlberg PG. Separation of acid and neutral cannabinoids in cannabis sativa L. using HPLC. In: Agurell S, Dewey WL WRE (Eds.), The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects, Academic Press, USA, 1984, pp. 79–88. https://doi.org/10.1016/B978-0-12-044620- 9.X5001-5. 10.53964/id.2024012Abdel-Salam OME, Abd El Baset M, Omara EA, Sleem AA. Protection by L-arginine against epinephrine-induced arrhythmia and cardiotoxicity. Innovation Discovery, Vol. 1, No. 2, 2024, pp. 12 . doi: 10.53964/id.2024012 10.1111/j.1476-5381.1976.tb06957.xAdams MD, Chait LD, Earnhardt JT. Tolerance to the cardiovascular effects of delta9- tetrahydrocannabinol in the rat. British Journal of Pharmacology, Vol. 56, No. 1, 1976, pp.43- 8. doi: 10.1111/j.1476-5381.1976.tb06957.x. 10.1016/0014-2999(80)90209-5Kawasaki H, Watanabe S, Ueki S. Effects of chronic administration of delta 9- tetrahydrocannabinol on the cardiovascular system, and pressor and behavioral responses to brain stimulation in freely moving rats. European Journal of Pharmacology, Vol. 65, No. 1, 1980, pp.63-9. doi: 10.1016/0014- 2999(80)90209-5. 10.1016/0024-3205(87)90559-5Estrada U, Brase DA, Martin BR, Dewey WL. Cardiovascular effects of delta 9- and delta 9(11)-tetrahydrocannabinol and their interaction with epinephrine. Life Science, Vol. 41, No. 1, 1987, pp.79-87. doi: 10.1016/0024- 3205(87)90559-5. 10.1089/can.2021.0188Gillett L, Johnson-Sasso C, Miller B, Shakowski C, Walker LA, Tompkins C. Arrhythmic effects of cannabis in ischemic heart disease. Cannabis and Cannabinoid Research, Vol. 8, No. 5, 2023, pp. 867-876. doi: 10.1089/can.2021.0188.doi: 10.1089/can.2021.0188. 10.1007/3-540-26573-2_20Pacher P, Bátkai S, Kunos G. Cardiovascular pharmacology of cannabinoids. Handbook of Experimental Pharmacology, Vol. 168, 2005, pp. 599-625. doi: 10.1007/3-540-26573-2_20. 10.1007/s11055-019-00736-wKrylatov AV, Maslov LN, Nam IF, Bushov YV. Cannabinoidergic regulation of the functional state of the heart. The role of the autonomic nervous system. Neuroscience and Behavioral Physiology, Vol. 49, No. 3, 2019. doi 10.1007/s11055-019-00736-w 10.1016/j.jacc.2014.06.1201Middlekauff HR, Park J, Moheimani RS. Adverse effects of cigarette and noncigarette smoke exposure on the autonomic nervous system: mechanisms and implications for cardiovascular risk. Journal of the American College of Cardiology, Vol. 64, No. 16, 2014, pp.1740-50. doi: 10.1016/j.jacc.2014.06.1201. 10.1055/s-0030-1248314Schmid K, Schönlebe J, Drexler H, MueckWeymann M. The effects of cannabis on heart rate variability and well-being in young men. Pharmacopsychiatry, Vol. 43, No. 4, 2010, pp.147-50. doi: 10.1055/s-0030-1248314. 10.1111/j.1440-1681.1981.tb00140.xLi DM. Tolerance to the effects of delta 1- tetrahydrocannabinol on the pressor responses to noradrenaline in rats. Clinical and Experimental Pharmacology and Physiology, Vol. 8, No. 2, 1981, pp.101-8. doi: 10.1111/j.1440-1681.1981.tb00140.x. 10.1161/01.cir.83.6.1888Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation, Vol. 83, No. 6, 1991, pp.1888-94. Jiménez-Candil J, Luengo CM. QT interval and acute myocardial ischemia: past promises, new evidences. Revista Española de Cardiología, Vol. 61, No. 6, 2008, pp.561-3 10.1155/2021/6621496Shah VD, Mohammad A, Nandkeolyar S, Stoletniy L, Contractor T. Torsades de Pointes due to excessive marijuana use in a susceptible patient. Case Reports in Cardiology, Vol. 2021:6621496, 2021. doi: 10.1155/2021/6621496. 10.1038/nature04710Sanguinetti M, Tristani-Firouzi M. hERG potassium channels and cardiac arrhythmia. Nature, Vol. 440, 2006, pp. 463–469. https://doi.org/10.1038/nature04710 10.1074/jbc.m116.743138Lamothe SM, Guo J, Li W, Yang T, Zhang S. The Human ether-a-go-go-related gene (herg) potassium channel represents an unusual target for protease-mediated damage. Journal of Biological Chemistry, Vol. 291, No. 39, 2016, pp.20387-401. doi: 10.1074/jbc.M116.743138. 10.1038/s41598-020-73165-2Orvos P, Pászti B, Topal L, Gazdag P, Prorok J, Polyák A, Kiss T, Tóth-Molnár E, CsuporLöffler B, Bajtel Á, Varró A, Hohmann J, Virág L, Csupor D. The electrophysiological effect of cannabidiol on hERG current and in guinea-pig and rabbit cardiac preparations. Scientific Reports, Vol. 10, No. 1, 2020, pp.16079. doi: 10.1038/s41598-020-73165-2. 10.1016/j.hrcr.2018.07.004Larsen TR, Kaszala K, Tan AY, Ellenbogen KA, Huizar JF. Paradoxical reflex bradycardia after epinephrine infusion for arrhythmia induction in the electrophysiology laboratory. Heart Rhythm Case Reports, Vol. 4, No. 10, 2018, pp. 456-457. https://doi.org/10.1016/j.hrcr.2018.07.004 10.1124/jpet.112.196816Rudź R, Schlicker E, Baranowska U, Marciniak J, Karabowicz P, Malinowska B. Acute myocardial infarction inhibits the neurogenic tachycardic and vasopressor response in rats via presynaptic cannabinoid type 1 receptor. The Journal of Pharmacology and Experimental Therapeutics, Vol. 343, No. 1, 2012, pp.198-205. doi: 10.1124/jpet.112.196816. 10.37394/23208.2023.20.15Abdel-Salam OME, Sayed MABM, Omara EA, Sleem AA. The effects of nitric oxide synthase inhibition on epinephrine-induced arrhythmia and myocardial damage. WSEAS Transactions on Biology and Biomedicine, Vol 20, 2023, pp.145-154. doi: 10.37394/23208.2023.20.15. 10.1016/0167-0115(92)90039-wRabkin SW. Dynorphin A (1-13) in the brain suppresses epinephrine-induced ventricular premature complexes and ventricular tachyarrhythmias. Regulatory Peptides, Vol. 41, No. 2, 1992, pp.95-107. 10.1007/s00210-002-0644-9Kawai Y, Hayashi Y, Ito I, Kamibayashi T, Takada K, Kagawa K, et al. Nicorandil prevents epinephrine-induced arrhythmias in halothane-anesthetized rats by nitric oxide dependent mechanism. Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 366, 2002, pp.522–527. 10.1111/j.1472-8206.2010.00836.xDhalla NS, Adameova A, Kaur M. Role of catecholamine oxidation in sudden cardiac death. Fundamental & Clinical Pharmacology, Vol. 24, No. 5, 2010, pp. 539–546. doi: 10.1111/j.1472-8206.2010.00836.x. 10.1139/y95-226Igić R. Mechanism of epinephrine-induced dysrhythmias in rat involves local cholinergic activation. Canadian Journal of Physiology and Pharmacology, Vol. 74, No. 1, 1996, pp. 85-8. 10.1016/j.cjca.2019.05.020Singh SM, Koh M, Fang J, Ko DT. The risk of cardiovascular events on cannabis' highest day. Canadian Journal of Cardiology, Vol. 35, No. 11, 2019, pp.1589-1591. doi: 10.1016/j.cjca.2019.05.020. 10.1111/add.15188Jakob J, Stalder O, Syrogiannouli L, Pletcher MJ, Vittinghoff E, Ning H, Tal K, Rana JS, Sidney S, Lloyd-Jones DM, Auer R. Association between marijuana use and electrocardiographic abnormalities by middle age: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Addiction, Vol. 116, No. 3, 2021, pp.583-95. doi: 10.1111/add.15188. Lu HC, Mackie K. An Introduction to the Endogenous Cannabinoid System. Biological Psychiatry, Vol. 79, 2016, pp. 516–25. 10.1016/j.bbamcr.2019.03.009Puhl SL. Cannabinoid-sensitive receptors in cardiac physiology and ischaemia. Biochimica et Biophysica Acta-Molecular Cell Research, Vol. 1867 No. 3, 2020, pp.118462. doi: 10.1016/j.bbamcr.2019.03.009. 10.1189/jlb.0703303Di Filippo C, Rossi F, Rossi S, D'Amico M. Cannabinoid CB2 receptor activation reduces mouse myocardial ischemia-reperfusion injury: involvement of cytokine/chemokines and PMN. Journal of Leukocyte Biology, Vol. 75, No. 3, 2004, 453-9. doi: 10.1189/jlb.0703303. 10.1159/000350088Li Q, Wang F, Zhang YM, Zhou JJ, Zhang Y. Activation of cannabinoid type 2 receptor by JWH133 protects heart against ischemia/reperfusion-induced apoptosis. Cellular Physiology and Biochemistry, Vol. 31, 2013, pp.693-702. doi: 10.1159/000350088 10.37394/232023.2022.2.3Abdel-Salam OME. The neurotoxic effects of cannabis on brain: Review of clinical and experimental data. Molecular Sciences and Applications, Vol. 2, 2022, pp.11-23. doi:10.37394/232023.2022.2.3